Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation

Yubin Ji, Yichen Liu, Nina Xue, Tingting Du, Liyuan Wang, Rui Huang, Ling Li, Chunhong Yan, Xiaoguang Chen

Research output: Contribution to journalArticle

Abstract

Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.

Original languageEnglish (US)
Pages (from-to)883-896
Number of pages14
JournalOncoTargets and Therapy
Volume12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Esophageal Neoplasms
Interleukin-6
Janus Kinase 2
Apoptosis
Salvia miltiorrhiza
Neoplasms
cryptotanshinone
Esophageal Squamous Cell Carcinoma
In Vitro Techniques
Cell Cycle Checkpoints
Heterografts
Cell Movement
Cell Survival
Flow Cytometry
Body Weight
Wounds and Injuries
Therapeutics
Growth

Keywords

  • Apoptosis
  • CTS
  • ESCC
  • Migration
  • Proliferation
  • Xenograft

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation. / Ji, Yubin; Liu, Yichen; Xue, Nina; Du, Tingting; Wang, Liyuan; Huang, Rui; Li, Ling; Yan, Chunhong; Chen, Xiaoguang.

In: OncoTargets and Therapy, Vol. 12, 01.01.2019, p. 883-896.

Research output: Contribution to journalArticle

Ji, Yubin ; Liu, Yichen ; Xue, Nina ; Du, Tingting ; Wang, Liyuan ; Huang, Rui ; Li, Ling ; Yan, Chunhong ; Chen, Xiaoguang. / Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation. In: OncoTargets and Therapy. 2019 ; Vol. 12. pp. 883-896.
@article{14bd2f3a0b8e4c97ac72fa5c7c086bb8,
title = "Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation",
abstract = "Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.",
keywords = "Apoptosis, CTS, ESCC, Migration, Proliferation, Xenograft",
author = "Yubin Ji and Yichen Liu and Nina Xue and Tingting Du and Liyuan Wang and Rui Huang and Ling Li and Chunhong Yan and Xiaoguang Chen",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/OTT.S187777",
language = "English (US)",
volume = "12",
pages = "883--896",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation

AU - Ji, Yubin

AU - Liu, Yichen

AU - Xue, Nina

AU - Du, Tingting

AU - Wang, Liyuan

AU - Huang, Rui

AU - Li, Ling

AU - Yan, Chunhong

AU - Chen, Xiaoguang

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.

AB - Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.

KW - Apoptosis

KW - CTS

KW - ESCC

KW - Migration

KW - Proliferation

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=85062698391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062698391&partnerID=8YFLogxK

U2 - 10.2147/OTT.S187777

DO - 10.2147/OTT.S187777

M3 - Article

AN - SCOPUS:85062698391

VL - 12

SP - 883

EP - 896

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -